FCS: Enhancing the Diagnosis

CME
30/05/2025 3 min

Listen "FCS: Enhancing the Diagnosis "

Descargar episodio Ver en sitio original

Episode Synopsis



Guest: Daniel Gaudet, MD, PhD



There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

More episodes of the podcast CME

When Topicals Fail: The New IPC Consensus Every Clinician Should Know 22/12/2025
Early Action in Obesity: Transforming Practice, Improving Outcomes 03/12/2025
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies 19/11/2025
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40% 18/11/2025
The Fifth Pillar? Closing the Gap in HFrEF 14/11/2025
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer 14/11/2025
MOA: CDH6-Targeted Antibody-Drug Conjugates 14/11/2025
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies 14/11/2025
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates 14/11/2025
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms 14/11/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA